Macquarie Stem Cells has provided this information to educate the public based on peer reviewed, published scientific and medical documents. We don’t aim to encourage consumers to seek out such treatments prior to an assessment by a health professional to determine your suitability for treatment. This is obtained directly from NCBI Pubmed Literature. There were no financial sponsors identified for this study. We aim to provide you with an unbiased range of treatments that are available aside from biological therapy, This is discussed in ‘other-options’ page on our website.
Before reading this article, it is important for you to understand, here at Macquarie Stem Cells, the biological treatment we perform focuses on treating osteoarthritis as well as issues associated with osteoarthritis. This publication is the newest Systematic Review available, in the abstract below, the authors briefly touch on conditions such as;
We have a lot of limitations and regulations in Australian Medicine, this is a good thing. These regulations ensure patient safety and significantly reduce the risk of ‘medical scams’. At this particular moment, we are seeing extremely good outcomes in relation to many different biological treatment methods for multiple conditions/diseases. It will take many years to introduce these treatments as ‘accepted medicine’. The biggest restriction at this stage is the lack of funding we have for clinical trials using biological treatments.
Clinical trials are the key to development of medical treatments in Australia. Clinical trials are the key to make significant progress with biological treatments.
Published: 15th May 2018
Stem Cells Journal
“The objective of this review is to describe the safety and efficacy of ASC and SVF in treating common diseases and the next steps in research that must occur prior to clinical use.”(Bateman, et al, 2018)
“Pubmed, Ovid Medline, Embase, Web of Science, and the Cochrane Library were searched for articles about use of SVF or ASC for disease therapy published between 2012 and 2017. One meta-analysis, 2 randomized controlled trials, and 16 case series were included, representing 844 human patients. 69 studies were performed in pre-clinical models of disease.”(Bateman, et al, 2018)
“ASCs improved symptoms, fistula healing, remission, and recurrence rates in severe cases of inflammatory bowel disease. In osteoarthritis, ASC and SVF improved symptom-related, functional, radiographic, and histological scores. ASC and SVF were also shown to improve clinical outcomes in ischemic stroke, multiple sclerosis, myocardial ischemia, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, chronic liver failure, glioblastoma, acute kidney injury, and chronic skin wounds. These effects were primarily paracrine in nature and mediated through reduction of inflammation and promotion of tissue repair. In the majority of human studies, autologous ASC and SVF from liposuction procedures were used, minimizing the risk to recipients. Very few serious, treatment-related adverse events were reported. The main adverse event was postprocedural pain.”(Bateman, et al, 2018)
“SVF and ASC are promising therapies for a variety of human diseases, particularly for patients with severe cases refractory to current medical treatments. Further randomized controlled trials must be performed to elaborate potential safety and efficacy prior to clinical use.”(Bateman, et al, 2018)
REF: Bateman, M., Strong, A., Gimble, J. and Bunnell, B. (2018). Using Fat to Fight Disease: A Systematic Review of Non-Homologous Adipose-Derived Stromal/Stem Cell Therapies. STEM CELLS.
TAGS: Macquarie Stem Cells, Possibilities of Biological Treatments, Focusing on Osteoarthritis, Macquarie Stem Cells treating osteoarthritis, Dr. Ralph Bright biological treatment
Remember, any surgical or invasive procedure carries risks. Before proceeding, you should seek a second opinion from an appropriately qualified health practitioner.